Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

11 Oct 2017

Abstract excerpt

17) cell activation. To investigate this possibility, we first defined the genes that are induced by IL-36 cytokines in primary human keratinocytes. This enabled us to demonstrate a significant IL-36 signature among the transcripts that are up-regulated in plaque psoriasis and the susceptibility loci associated with the disease in genome-wide studies. Next, we investigated the impact of in vivo and ex vivo IL-36...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatology and Skin Diseases
Share to Psoriasis: Treatment and Pathogenesis
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29021166
DOI: 10.1126/scitranslmed.aan2514

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic targetPMID 29021166Read ↗

The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.Semantic proximity Read ↗

IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitisSemantic proximity Read ↗

The role of interleukin‐36 in health and disease statesSemantic proximity Read ↗

IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymoreSemantic proximity Read ↗

RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene SignatureSemantic proximity Read ↗

Deficiency of IL-36 receptor antagonist (DITRA) is associated with decreased homoeostatic CCL27 expression leading to heightened dermal inflammationSemantic proximity Read ↗

Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalkSemantic proximity Read ↗

Novel IL36RN Mutation Identified in Pediatric-Onset Generalized Pustular Psoriasis Causes IL36 Antagonist DegradationSemantic proximity Read ↗

Cutaneous findings and treatments in deficiency of interleukin-36 receptor antagonist (DITRA): A review of the literature.Semantic proximity Read ↗

Interleukin-36 receptor antagonist deficiency patient with a novel mutation.Semantic proximity Read ↗

Molecular aspects of Interleukin-36 cytokine activation and regulationSemantic proximity Read ↗

IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.